H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Aprea Therapeutics (APRE) to $4 from $5 and keeps a Buy rating on the shares. The firm is “encouraged by the positive,” early proof-of-concept data from the ACESOT-1051 study. Aprea reported “promising” preliminary signals from an endometrial cancer patient, the analyst tells investors in a research note. H.C. Wainwright cites dilution for the target cut.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APRE:
- Aprea Therapeutics prices 6.29M shares at 89c in private placement
- Aprea Therapeutics announces early PoC data in ACESOT-1051 trial
- Aprea Therapeutics Updates Oncology Pipeline and Strategy Outlook
- Aprea Therapeutics files to sell 5.5M shares of common stock for holders
- Advancing APR-1051 in HPV-Positive Cancers and Extended Cash Runway Underpin Aprea Therapeutics Buy Rating and $5 Target